Linked Life Data

19936876

Source:http://linkedlifedata.com/resource/pubmed/id/19936876

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19936876rdf:typepubmed:Citationlld:pubmed
pubmed-article:19936876lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C0242602lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C1328050lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:19936876lifeskim:mentionsumls-concept:C0075804lld:lifeskim
pubmed-article:19936876pubmed:issue5lld:pubmed
pubmed-article:19936876pubmed:dateCreated2010-1-21lld:pubmed
pubmed-article:19936876pubmed:abstractTextThe efficacy and safety of high-dose chemotherapy with tandem autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in a multicenter clinical study of patients with advanced multiple myeloma. Eligible patients (n = 40) were consecutively enrolled in the phase I/II study and received 2-4 cycles of vincristine-adriamycin-dexamethasone regimen. The responding patients underwent PBSC harvesting following high-dose cyclophosphamide and filgrastim administration. The first auto-PBSCT (n = 32) following high-dose melphalan (200 mg/m(2)) was performed within 2 months of PBSC harvesting; the second auto-PBSCT (n = 28) was scheduled 3-6 months later. Treatment-related mortality was 2.5% (n = 1) throughout the protocol. Grade 4 nonhematologic toxicity occurred in 12.5 and 14.3% of the first and second auto-PBSCT patients, respectively. All but one patient (who died) achieved hematopoietic recovery. For the 28 patients completing the second auto-PBSCT, the results were favorable with a response rate of 65% (complete response rate = 27.5%, n = 11); the five-year progression-free survival and overall survival were 20.3 and 66.5%, respectively. In conclusion, high-dose chemotherapy with tandem auto-PBSCT is feasible and safe with a favorable response rate in treating advanced multiple myeloma in Japan.lld:pubmed
pubmed-article:19936876pubmed:languageenglld:pubmed
pubmed-article:19936876pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19936876pubmed:citationSubsetIMlld:pubmed
pubmed-article:19936876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19936876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19936876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19936876pubmed:statusMEDLINElld:pubmed
pubmed-article:19936876pubmed:monthDeclld:pubmed
pubmed-article:19936876pubmed:issn1865-3774lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:HaradaMineMlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:TsudaHiroyuki...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:SakaiAkiraAlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:GondoHisashiHlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:MiwaAkiyoshiAlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:MiyataAkiraAlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:ShimazakiChih...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:TakemotoYoshi...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:ShinagawaKats...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:TajimaFumihit...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:TamakiShigehi...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:SunamiKazutak...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:ImamuraYutaka...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:SawamuraMorio...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:HinoNorihikoNlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:MizunoIshikaz...lld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:ChouTakaakiTlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:SaburiYoshioYlld:pubmed
pubmed-article:19936876pubmed:authorpubmed-author:KamimuraTomoh...lld:pubmed
pubmed-article:19936876pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19936876pubmed:volume90lld:pubmed
pubmed-article:19936876pubmed:ownerNLMlld:pubmed
pubmed-article:19936876pubmed:authorsCompleteYlld:pubmed
pubmed-article:19936876pubmed:pagination635-42lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:meshHeadingpubmed-meshheading:19936876...lld:pubmed
pubmed-article:19936876pubmed:year2009lld:pubmed
pubmed-article:19936876pubmed:articleTitlePhase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.lld:pubmed
pubmed-article:19936876pubmed:affiliationDivision of Hematology, Department of Internal Medicine, National Hospital Organization Okayama Medical Center, Kitaku, Okayama, 701-1192, Japan. kazusuna@pop12.odn.ne.jplld:pubmed
pubmed-article:19936876pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19936876pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:19936876pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:19936876pubmed:publicationTypeClinical Trial, Phase Illd:pubmed